Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 34Prostatic Neoplasms 32Neoplasms 28Multiple Myeloma 26Pancreatic Neoplasms 25Brain Neoplasms 23Colorectal Neoplasms 19Recurrence 18Squamous Cell Carcinoma of Head and Neck 16Melanoma 16Lymphoma 15Neoplasm Metastasis 14Lung Neoplasms 14Sarcoma 13Lymphoma, B-Cell 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Leukemia, Myeloid, Acute 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Skin Neoplasms 8Neuroblastoma 8Lymphoma, Non-Hodgkin 8Colonic Neoplasms 8Carcinoma, Renal Cell 8

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Epithelial Ovarian × 1 year × Clear all
NCT05053750 2026-04-15

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Gynecologic

Epithelial Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡